{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:28:17Z","timestamp":1793107697757,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cardiac resynchronization therapy (CRT) improves outcomes in heart failure patients with wide QRS complex. However, CRT management following continuous flow Left Ventricular Assist Device (LVAD) implant vary: some centers continue CRT while others turn off the left ventricular (LV) lead at LVAD implant. We sought to study the effect of continued CRT versus turning off CRT pacing following continuous flow LVAD implantation. A comprehensive retrospective multicenter cohort of 295 patients with LVAD and pre-existing CRT was studied. CRT was programmed off after LVAD implant in 44 patients. We compared their outcomes to the rest of the cohort using univariate and multivariate models. Mean age was 60\u2009\u00b1\u200912 years, 83% were males, 52% had ischemic cardiomyopathy and 54% were destination therapy. Mean follow-up was 2.4\u2009\u00b1\u20092.0 years, and mean LVAD support time was 1.7\u2009\u00b1\u20091.4 years. Patients with CRT OFF had a higher Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) mean profile (3.9 vs 3.3, p\u2009=\u20090.01), more secondary prevention indication for a defibrillator (64.9% vs 44.5%, p\u2009=\u20090.023), and more pre-LVAD ventricular arrhythmias (VA) (77% vs 60%, p\u2009=\u20090.048). There were no differences between the CRT OFF and CRT ON groups in overall mortality (Log rank p\u2009=\u20090.32, adjusted HR\u2009=\u20091.14 [0.54\u20132.22], p\u2009=\u20090.71), heart transplantation, cardiac and noncardiac mortality, all cause hospitalizations, hospitalizations for ICD shocks, and number and frequency of ICD shocks or anti-tachycardia pacing therapy. There were no differences in post LVAD atrial arrhythmias (AA) (Adjusted OR\u2009=\u20090.45 [0.18\u20131.06], p\u2009=\u20090.31) and ventricular arrhythmias (OR\u2009=\u20090.65 [0.41\u20131.78], p\u2009=\u20090.41). There was no difference in change in LVEF, LV end diastolic and end systolic diameters between the 2 groups. Our study suggests that turning off CRT pacing after LVAD implantation in patients with previous CRT pacing did not affect mortality, heart transplantation, device therapies or arrhythmia burden. A prospective study is needed to confirm these findings.<\/jats:p>","DOI":"10.1038\/s41598-020-59117-w","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:03:11Z","timestamp":1581591791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Continued versus Suspended Cardiac Resynchronization Therapy after Left Ventricular Assist Device Implantation"],"prefix":"10.1038","volume":"10","author":[{"given":"Henri","family":"Roukoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Bhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cowger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munazzah","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimin R.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Slaughter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Gopinathannair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"59117_CR1","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","volume":"350","author":"MR Bristow","year":"2004","unstructured":"Bristow, M. R. et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350, 2140\u20132150 (2004).","journal-title":"N Engl J Med"},{"key":"59117_CR2","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa050496","volume":"352","author":"JG Cleland","year":"2005","unstructured":"Cleland, J. G. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352, 1539\u20131549 (2005).","journal-title":"N Engl J Med"},{"key":"59117_CR3","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jacc.2014.06.1178","volume":"64","author":"F Leyva","year":"2014","unstructured":"Leyva, F., Nisam, S. & Auricchio, A. 20 years of cardiac resynchronization therapy. J Am Coll Cardiol 64, 1047\u20131058 (2014).","journal-title":"J Am Coll Cardiol"},{"key":"59117_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/hc0402.102623","volume":"105","author":"CM Yu","year":"2002","unstructured":"Yu, C. M. et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 105, 438\u2013445 (2002).","journal-title":"Circulation"},{"key":"59117_CR5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.jacc.2012.05.057","volume":"60","author":"G Ouellet","year":"2012","unstructured":"Ouellet, G. et al. Effect of cardiac resynchronization therapy on the risk of first and recurrent ventricular tachyarrhythmic events in MADIT-CRT. J Am Coll Cardiol 60, 1809\u20131816 (2012).","journal-title":"J Am Coll Cardiol"},{"key":"59117_CR6","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.jacc.2011.08.038","volume":"58","author":"J Thijssen","year":"2011","unstructured":"Thijssen, J. et al. Implantable cardioverter-defibrillator patients who are upgraded and respond to cardiac resynchronization therapy have less ventricular arrhythmias compared with nonresponders. J Am Coll Cardiol 58, 2282\u20132289 (2011).","journal-title":"J Am Coll Cardiol"},{"key":"59117_CR7","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.jacc.2005.04.067","volume":"46","author":"C Ermis","year":"2005","unstructured":"Ermis, C. et al. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 46, 2258\u20132263 (2005).","journal-title":"J Am Coll Cardiol"},{"key":"59117_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.hrthm.2010.12.031","volume":"8","author":"MR Gold","year":"2011","unstructured":"Gold, M. R., Linde, C., Abraham, W. T., Gardiwal, A. & Daubert, J. C. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm 8, 679\u2013684 (2011).","journal-title":"Heart Rhythm"},{"key":"59117_CR9","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1056\/NEJMoa0909938","volume":"361","author":"MS Slaughter","year":"2009","unstructured":"Slaughter, M. S. et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 361, 2241\u20132251 (2009).","journal-title":"N Engl J Med"},{"key":"59117_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/HCO.0b013e328345af13","volume":"26","author":"SG Drakos","year":"2011","unstructured":"Drakos, S. G. et al. Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action. Curr Opin Cardiol 26, 245\u2013255 (2011).","journal-title":"Curr Opin Cardiol"},{"key":"59117_CR11","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.jacc.2009.12.052","volume":"55","author":"JG Rogers","year":"2010","unstructured":"Rogers, J. G. et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol 55, 1826\u20131834 (2010).","journal-title":"J Am Coll Cardiol"},{"key":"59117_CR12","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.amjcard.2016.05.050","volume":"118","author":"JW Schleifer","year":"2016","unstructured":"Schleifer, J. W. et al. Effect of Continued Cardiac Resynchronization Therapy on Ventricular Arrhythmias After Left Ventricular Assist Device Implantation. Am J Cardiol 118, 556\u2013559 (2016).","journal-title":"Am J Cardiol"},{"key":"59117_CR13","doi-asserted-by":"publisher","unstructured":"Richardson, T. D. et al. Prospective Randomized Evaluation of Implantable Cardioverter-Defibrillator Programming in Patients With a Left Ventricular Assist Device. Journal of the American Heart Association 7, https:\/\/doi.org\/10.1161\/jaha.1117.007748 (2018).","DOI":"10.1161\/jaha.1117.007748"},{"key":"59117_CR14","doi-asserted-by":"publisher","unstructured":"Gopinathannair, R. et al. Cardiac Resynchronization Therapy and Clinical Outcomes in Continuous Flow Left Ventricular Assist Device Recipients. Journal of the American Heart Association 7, https:\/\/doi.org\/10.1161\/jaha.1118.009091 (2018).","DOI":"10.1161\/jaha.1118.009091"},{"key":"59117_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10741-018-9740-x","volume":"24","author":"DC Voruganti","year":"2019","unstructured":"Voruganti, D. C. et al. Cardiac resynchronization therapy and outcomes in patients with left ventricular assist devices: a systematic review and meta-analysis. Heart failure reviews 24, 229\u2013236 (2019).","journal-title":"Heart failure reviews"},{"key":"59117_CR16","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1016\/j.healun.2017.01.472","volume":"36","author":"AR Garan","year":"2017","unstructured":"Garan, A. R. et al. Cardiac Resynchronization Therapy Reduces Mortality and Cardiovascular Readmissions in Left Ventricular Assist Device Recipients. The Journal of Heart and Lung Transplantation 36, S179\u2013S180 (2017).","journal-title":"The Journal of Heart and Lung Transplantation"},{"key":"59117_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cardfail.2014.12.006","volume":"21","author":"R Gopinathannair","year":"2015","unstructured":"Gopinathannair, R. et al. Impact of cardiac resynchronization therapy on clinical outcomes in patients with continuous-flow left ventricular assist devices. J Card Fail 21, 226\u2013232 (2015).","journal-title":"J Card Fail"},{"key":"59117_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.amjcard.2018.09.022","volume":"123","author":"V Cotarlan","year":"2019","unstructured":"Cotarlan, V. et al. Usefulness of Cardiac Resynchronization Therapy in Patients With Continuous Flow Left Ventricular Assist Devices. Am J Cardiol 123, 93\u201399 (2019).","journal-title":"Am J Cardiol"},{"key":"59117_CR19","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.hrthm.2017.08.022","volume":"15","author":"H Roukoz","year":"2018","unstructured":"Roukoz, H. et al. B-AB18-06: Continued CRT versus Turning Off Left Ventricular Lead after Left Ventricular Assist Device Implant: A Multicenter Experience. Heart Rhythm 15, S48 (2018).","journal-title":"Heart Rhythm"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59117-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59117-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59117-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T06:38:29Z","timestamp":1670308709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59117-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["59117"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-59117-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"5 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Roukoz has received consulting fees from Boston Scientific and speaking fees from Medtronic. Dr. Ravichandran has been a speaker for Abbott Medical. Dr. Gopinathannair is a consultant and\/or speaker for Abbott Medical, Boston Scientific, Pfizer, Bristol Myers Squibb, and Zoll Medical. He also serves as a physician advisor for HealthTrust PG and Abiomed and has received research grant from Boston Scientific. Dr. Slaughter has received research grant funding from Heartware Inc. and serves on the advisory board for Oregon Heart (no compensation). Dr. Cowger is a paid speaker for Abbott and Medtronic and is on the Medtronic Advisory Board. Henry Ford receives clinical trial research funds from both Medtronic and Abbott. The remaining authors have no disclosures to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2573"}}